Huilan He , Yun Zheng , Jinlong Ji , Chunlian Ye , Yu Sun , Yuwei Peng , Ying Zhang , Zhiyuan Zhong
{"title":"脂质体全反式维甲酸通过缓解肿瘤干细胞和修复肿瘤微环境来增强放疗的抗肿瘤免疫","authors":"Huilan He , Yun Zheng , Jinlong Ji , Chunlian Ye , Yu Sun , Yuwei Peng , Ying Zhang , Zhiyuan Zhong","doi":"10.1016/j.jconrel.2025.113995","DOIUrl":null,"url":null,"abstract":"<div><div>Radiotherapy (RT) induces immunogenic cell death but also promotes immunosuppression, cancer stemness and immune evasion, thus compromising anti-tumor immune response and leading to cancer recurrence and metastasis. Here, we developed liposomal all-trans retinoic acid nanoparticles (LATRA) to simultaneously mitigate cancer stemness and remedy suppressive tumor microenvironment, which on one hand decreases tumorigenicity and sensitizes tumors to RT and on the other hand stimulates dendritic cell maturation and reprograms macrophages toward a pro-inflammatory M1 phenotype. In murine colorectal tumor model, RT combined with LATRA essentially reduces tumor burden, prevents recurrence and induces a durable immune response with memory effects. Notably, LATRA effectively eradicates residual tumor cells in post-surgery 4T1 breast tumor model, avoiding tumor relapse and lung metastasis. Liposomal all-trans retinoic acid offers a new and promising strategy to empower RT-induced anti-tumor immunity.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"385 ","pages":"Article 113995"},"PeriodicalIF":10.5000,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Liposomal all-trans retinoic acid boosts anti-tumor immunity of radiotherapy via mitigating cancer stemness and remedying tumor microenvironment\",\"authors\":\"Huilan He , Yun Zheng , Jinlong Ji , Chunlian Ye , Yu Sun , Yuwei Peng , Ying Zhang , Zhiyuan Zhong\",\"doi\":\"10.1016/j.jconrel.2025.113995\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Radiotherapy (RT) induces immunogenic cell death but also promotes immunosuppression, cancer stemness and immune evasion, thus compromising anti-tumor immune response and leading to cancer recurrence and metastasis. Here, we developed liposomal all-trans retinoic acid nanoparticles (LATRA) to simultaneously mitigate cancer stemness and remedy suppressive tumor microenvironment, which on one hand decreases tumorigenicity and sensitizes tumors to RT and on the other hand stimulates dendritic cell maturation and reprograms macrophages toward a pro-inflammatory M1 phenotype. In murine colorectal tumor model, RT combined with LATRA essentially reduces tumor burden, prevents recurrence and induces a durable immune response with memory effects. Notably, LATRA effectively eradicates residual tumor cells in post-surgery 4T1 breast tumor model, avoiding tumor relapse and lung metastasis. Liposomal all-trans retinoic acid offers a new and promising strategy to empower RT-induced anti-tumor immunity.</div></div>\",\"PeriodicalId\":15450,\"journal\":{\"name\":\"Journal of Controlled Release\",\"volume\":\"385 \",\"pages\":\"Article 113995\"},\"PeriodicalIF\":10.5000,\"publicationDate\":\"2025-06-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Controlled Release\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0168365925006169\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MULTIDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Controlled Release","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0168365925006169","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
Liposomal all-trans retinoic acid boosts anti-tumor immunity of radiotherapy via mitigating cancer stemness and remedying tumor microenvironment
Radiotherapy (RT) induces immunogenic cell death but also promotes immunosuppression, cancer stemness and immune evasion, thus compromising anti-tumor immune response and leading to cancer recurrence and metastasis. Here, we developed liposomal all-trans retinoic acid nanoparticles (LATRA) to simultaneously mitigate cancer stemness and remedy suppressive tumor microenvironment, which on one hand decreases tumorigenicity and sensitizes tumors to RT and on the other hand stimulates dendritic cell maturation and reprograms macrophages toward a pro-inflammatory M1 phenotype. In murine colorectal tumor model, RT combined with LATRA essentially reduces tumor burden, prevents recurrence and induces a durable immune response with memory effects. Notably, LATRA effectively eradicates residual tumor cells in post-surgery 4T1 breast tumor model, avoiding tumor relapse and lung metastasis. Liposomal all-trans retinoic acid offers a new and promising strategy to empower RT-induced anti-tumor immunity.
期刊介绍:
The Journal of Controlled Release (JCR) proudly serves as the Official Journal of the Controlled Release Society and the Japan Society of Drug Delivery System.
Dedicated to the broad field of delivery science and technology, JCR publishes high-quality research articles covering drug delivery systems and all facets of formulations. This includes the physicochemical and biological properties of drugs, design and characterization of dosage forms, release mechanisms, in vivo testing, and formulation research and development across pharmaceutical, diagnostic, agricultural, environmental, cosmetic, and food industries.
Priority is given to manuscripts that contribute to the fundamental understanding of principles or demonstrate the advantages of novel technologies in terms of safety and efficacy over current clinical standards. JCR strives to be a leading platform for advancements in delivery science and technology.